~ Buy the SIVEXTRO (tedizolid phosphate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SIVEXTRO

All Clinical Trials for SIVEXTRO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02342418 ↗	Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults	Completed	Merck Sharp & Dohme Corp.	Phase 4	2015-03-01	This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.
NCT02342418 ↗	Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults	Completed	Albany College of Pharmacy and Health Sciences	Phase 4	2015-03-01	This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.
NCT02342418 ↗	Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults	Completed	Amit.Pai	Phase 4	2015-03-01	This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.
NCT02620787 ↗	Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis	Completed	Merck Sharp & Dohme Corp.	Phase 1	2016-02-23	This study will determine the tissue penetration of tedizolid (Sivextro, Merck & Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.
NCT02620787 ↗	Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis	Completed	Hartford Hospital	Phase 1	2016-02-23	This study will determine the tissue penetration of tedizolid (Sivextro, Merck & Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.

Clinical Trial Conditions for SIVEXTRO

Condition Name

Condition Name for SIVEXTRO
Intervention	Trials
Bone and Joint Infection	1
Diabetes	1
Gram-Positive Bacterial Infections	1
Healthy Volunteers	1

Condition MeSH

Condition MeSH for SIVEXTRO
Intervention	Trials
Infections	3
Infection	3
Communicable Diseases	2
Wounds and Injuries	1

Clinical Trial Locations for SIVEXTRO

Trials by Country

Trials by Country for SIVEXTRO
Location	Trials
United States	10
France	1

Trials by US State

Trials by US State for SIVEXTRO
Location	Trials
California	2
North Carolina	1
New York	1
Nebraska	1
Missouri	1

Clinical Trial Progress for SIVEXTRO

Clinical Trial Phase

Clinical Trial Phase for SIVEXTRO
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status for SIVEXTRO
Clinical Trial Phase	Trials
Completed	3
Not yet recruiting	1
Active, not recruiting	1

Clinical Trial Sponsors for SIVEXTRO

Sponsor Name

Sponsor Name for SIVEXTRO
Sponsor	Trials
Merck Sharp & Dohme Corp.	3
Hartford Hospital	1
Los Angeles Biomedical Research Institute	1

Sponsor Type

Sponsor Type for SIVEXTRO
Sponsor	Trials
Other	6
Industry	3